Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases and is particularly aggressive with a 5 year survival rate of just 5-10%. Historically, drug development in this indication has been largely unsuccessful, meaning drug treatment options are limited and the use of platinum-based therapy has remained the cornerstone of therapy for many years. SCLC treatment is yet to benefit from the emergence of targeted therapies and biomarker-associated treatments used in other oncology indications. Immune checkpoint inhibitors are now in Phase III clinical development for SCLC; these novel therapies hold promise of fulfilling the high unmet need for more effective therapies in this difficult-to-treat indication.

Questions Answered in This Report:

  • The highest incidence of SCLC occurs in people aged 50-85; smoking being the greatest risk factor. What is the size of the U.S. and EU5 SCLC patient populations and how will it change over a 10-year period? What are the key SCLC drug-treatable populations of commercial interest?

  • Treatment of SCLC involves chemotherapy, radiotherapy and very rarely surgery. What type of practitioner assumes care of SCLC patients and how does it differ depending on the stage of the disease and/or the geographical market? How are physicians currently managing treatment of SCLC patients?

  • Immune checkpoint inhibitors are now in Phase III clinical development for SCLC. What do experts interviewed think about the prospects of these emerging therapies? Which agents, if any, do we forecast will launch for the treatment of SCLC and how, if at all, will these launches impact the SCLC landscape?

  • We have identified several unmet needs, challenges, and opportunities in the SCLC landscape. What are the key unmet needs in the treatment of SCLC according to interviewed thought leaders? Is it likely that these unmet needs will be addressed or partially addressed during our forecast period?


Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.

Primary research: 8 country-specific interviews with thought-leading medical oncologists.

Epidemiology: Diagnosed incident cases of SCLC cancer by stage of disease. Clinical- and market-relevant drug-treatable populations.

Population segments in market forecast: Limited-disease SCLC; first-line extensive-disease SCLC; second-line extensive-disease SCLC; third-line extensive-disease SCLC.

Emerging therapies: Coverage of Phase III and select Phase II drugs. Coverage of select preclinical and Phase I products.

Author(s): Steven Tinsley, Ph.D., M.Sc.